Literature DB >> 24900014

Radiosynthesis of (99m)Tc(CO)3-Clinafloxacin Dithiocarbamate and Its Biological Evaluation as a Potential Staphylococcus aureus Infection Radiotracer.

Syed Qaiser Shah1, Mohammad Rafiullah Khan2, Syed Mohammad Ali3.   

Abstract

BACKGROUND: Clinafloxacin dithiocarbamate (CNND) was radiolabeled with technetium-99m ((99m)Tc) using [(99m)Tc(CO)3(H2O)3](+) and assessed for its radiochemical stability in saline and serum, its in vitro binding with methicillin-resistant Staphylococcus aureus (MRSA) and biodistribution in female nude mice (FNM) artificially infected with live and heat-killed MRSA.
METHODS: In normal saline (NS) the (99m)Tc(CO)3-clinafloxacin dithiocarbamate ((99m)Tc(CO)3-CNND) showed radiochemical stability with a maximum value of 99.10 ± 0.20% and remained stable up to 4 h (92.65 ± 0.18%).
RESULTS: In human serum at 37°C within 16 h of incubation, 14.85% side products as a result of de-tagging developed. Incubation with MRSA gave saturated binding with a maximum value of 72.75 ± 1.20%. Almost six-fold higher uptake was seen in the infected muscle of the FNM as compared to the inflamed and normal muscle. The (99m)Tc(CO)3-CNND complex showed a normal route of excretion from the body of the FNM model.
CONCLUSION: The higher stability in NS, HS, saturated in vitro binding with a live strain of MRSA and six-fold higher uptake in the target organ showed the (99m)Tc(CO)3-CNND complex to be a potential MRSA infection radiotracer.

Entities:  

Keywords:  99mTc(CO)3-Clinafloxacin dithiocarbamate complex; Infection radiotracer; MRSA

Year:  2011        PMID: 24900014      PMCID: PMC4043045          DOI: 10.1007/s13139-011-0106-8

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  8 in total

1.  In vitro photogenotoxic activity of clinafloxacin: a paradigm predicting photocarcinogenicity.

Authors:  S J Bulera; J C Theiss; T A Festerling; F A de la Iglesia
Journal:  Toxicol Appl Pharmacol       Date:  1999-05-01       Impact factor: 4.219

2.  Radiosynthesis and biodistribution of (99m)Tc-rifampicin: a novel radiotracer for in-vivo infection imaging.

Authors:  Syed Qaiser Shah; Aakif Ullah Khan; Muhammad Rafiullah Khan
Journal:  Appl Radiat Isot       Date:  2010-06-02       Impact factor: 1.513

3.  Neutrophil labeling with [(99m)Tc]-technetium stannous colloid is complement receptor 3-mediated and increases the neutrophil priming response to lipopolysaccharide.

Authors:  Hayley Gallagher; Stuart C Ramsay; Jodie Barnes; Jacqueline Maggs; Nathan Cassidy; Natkunam Ketheesan
Journal:  Nucl Med Biol       Date:  2006-03-09       Impact factor: 2.408

4.  Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations.

Authors:  M M Welling; A Paulusma-Annema; H S Balter; E K Pauwels; P H Nibbering
Journal:  Eur J Nucl Med       Date:  2000-03

5.  (99m)Tc-prulifloxacin in artificially infected animals. Radiosynthesis and biological evaluation.

Authors:  S Q Shah; A U Khan; M R Khan
Journal:  Nuklearmedizin       Date:  2011-02-21       Impact factor: 1.379

6.  Infection imaging using whole-body FDG-PET.

Authors:  K D Stumpe; H Dazzi; A Schaffner; G K von Schulthess
Journal:  Eur J Nucl Med       Date:  2000-07

7.  Open-label, multicentre, emergency-use study of clinafloxacin (CI-960) in the treatment of patients with serious life-threatening infections.

Authors:  P Shah; U Trostmann; K Tack
Journal:  Int J Antimicrob Agents       Date:  2002-03       Impact factor: 5.283

8.  Synthesis of (99m)TcN-clinafloxacin Dithiocarbamate Complex and Comparative Radiobiological Evaluation in Staphylococcus aureus Infected Mice.

Authors:  Syed Qaiser Shah; Mohammad Rafiullah Khan
Journal:  World J Nucl Med       Date:  2014-09
  8 in total
  1 in total

Review 1.  Ciprofloxacin: from infection therapy to molecular imaging.

Authors:  Syed Ali Raza Naqvi; Samina Roohi; Anam Iqbal; Tauqir A Sherazi; Ameer Fawad Zahoor; Muhammad Imran
Journal:  Mol Biol Rep       Date:  2018-07-04       Impact factor: 2.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.